Investor's Business Daily on MSN20h
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer DrugAstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...
It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...
The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan ...
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...
Additionally, the impact of other drugs, such as Enhertu and Trodelvy, has been identified as a confounding factor in the trial results, as they were approved during the trial period and allowed for ...
Linda Nolan is to start a new cancer drug after scans showed the tumours in her brain have grown. The singer, 65, part of the ...
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback